Dare Bioscience Inc (Dare Bioscience) is a biopharmaceutical company that develops products for women’s reproductive health. Its product pipeline includes Ovaprene, an investigational hormone-free monthly intravaginal contraceptive designed to be worn conveniently over multiple weeks, Sildenafil a phosphodiesterase-5 (PDE-5) inhibitor and XACIATO for the treatment of of bacterial vaginosis in females 12 years of age and older. Dare Bioscience's also provides DARE-PDMI, DARE-PDMI, DARE VVA1, DARE FRTI/PTBI, DARE-LARC1 and DARE-RH1, among others. The company develops and markets therapies for women in the areas of contraception, vaginal health, sexual health and fertility. Dare Bioscience is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
3655 Nobel Dr Ste 260, San Diego, California, 92122-1050
Website
www.darebioscience.com
Telephone
1 858 9267655
No of Employees
23
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DARE (NASD)
Revenue (2022)
$2.8M
-71.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
2.5%
(2022 vs 2021)
Market Cap*
$28.8M
Net Profit Margin (2022)
XYZ
-247.1%
(2022 vs 2021)
* As of and is in US$
Dare Bioscience Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Ovaprene | Ovaprene |
| Sildenafil | |
| XACIATO (clindamycin phosphate) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with Organon to accelerate the development of much-needed, innovative medicines for women |
| 2021 | Contracts/Agreements | In July, the company entered into a cooperative research and development agreement (CRADA) with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) for the pivotal Phase 3 study of Ovaprene. |
| 2020 | Contracts/Agreements | In September, the company and Avomeen entered into a partnership to accelerate the development of Dare’s novel pipeline of women’s health programs. |
Competitor Comparison
| Key Parameters | Dare Bioscience Inc | Seagen Inc | ImmunoGen Inc | Nektar Therapeutics | Allena Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | Bothell | Waltham | San Francisco | Sudbury |
| State/Province | California | Washington | Massachusetts | California | Massachusetts |
| No. of Employees | 23 | 3,256 | 277 | 137 | 21 |
| Entity Type | Public | Private | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William H. Rastetter | Chairman | Executive Board | 2019 | 75 |
| Sabrina Martucci Johnson | Director; President; Chief Executive Officer | Executive Board | 2017 | 56 |
| MarDee Haring-Layton | Chief Accounting Officer | Senior Management | 2024 | - |
| David Friend | Chief Scientific Officer | Senior Management | 2018 | - |
| Robert Charboneau | Vice President - Manufacturing and Supply Chain | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer